Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial

IMPORTANCE: Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective A...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Tufia C., Suman, Vera J., D’Assoro, Antonino B., Carter, Jodi M., Giridhar, Karthik V., McMenomy, Brendan P., Santo, Katelyn, Mayer, Erica L., Karuturi, Meghan S., Morikawa, Aki, Marcom, P. Kelly, Isaacs, Claudine J., Oh, Sun Young, Clark, Amy S., Mayer, Ingrid A., Keyomarsi, Khandan, Hobday, Timothy J., Peethambaram, Prema P., O’Sullivan, Ciara C., Leon-Ferre, Roberto A., Liu, Minetta C., Ingle, James N., Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999287/
https://www.ncbi.nlm.nih.gov/pubmed/36892847
http://dx.doi.org/10.1001/jamaoncol.2022.7949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999287/
https://www.ncbi.nlm.nih.gov/pubmed/36892847
http://dx.doi.org/10.1001/jamaoncol.2022.7949

Ejemplares similares